Addleshaw Goddard advises Longwall Ventures on the closing of Longwall Fund 4

Addleshaw Goddard has advised Longwall Venture Partners LLP (“Longwall”), a leading UK deeptech venture capital manager, on the successful closing of Longwall Fund 4. The fund is anchored by a cornerstone commitment of up to £50 million from the British Business Bank through its Enterprise Capital Funds programme. Longwall Fund 4 will continue Longwall’s established strategy of backing early-stage UK science and engineering companies, with a focus on sectors including advanced manufacturing, clean energy, defence, and life sciences.

Founded in 2008, Longwall has a strong track record of supporting breakthrough technologies and commercialising scientific research. It’s portfolio spans more than 50 companies across medical devices, aerospace, and defence applications. Notably, Longwall was an early investor in OrganOx, which was sold to Terumo Corporation in 2025 for over $1.5 billion – one of the UK’s largest medtech exits – delivering a 19.2x return for Longwall’s investors.

The Addleshaw Goddard team was led by private funds partner Ben Cocoracchio, supported by associate Anjuli Muscutt and tax partner Zoe Fatchen.

Ben Cocoracchio commented:

“We are thrilled to have supported Longwall Ventures on the successful closing of Fund 4. The fund’s focus on commercialising UK scientific and engineering innovation is vital for the continued growth of the UK’s deeptech sector. This close, anchored by the British Business Bank, is a testament to Longwall’s reputation and the strength of their track record. Congratulations to the Longwall team on this important milestone.”